Monthly Archives: December 2015
Virtues in Business
Here’s a new paper on the popular-but-contested notion of “virtue”, in the latest issue of the Business Ethics Quarterly. >>> Virtuous Persons and Virtuous Actions in Business Ethics and Organizational Research, by Miguel Alzola Abstract: The language of virtue is
Virtues in Business
Here’s a new paper on the popular-but-contested notion of “virtue”, in the latest issue of the Business Ethics Quarterly. >>> Virtuous Persons and Virtuous Actions in Business Ethics and Organizational Research, by Miguel Alzola Abstract: The language of virtue is
A “Relational” Approach to Egalitarianism & Executive Compensation
A new paper by one of our favourite authors, in the latest issue of the Journal of Business Ethics. >>> Egalitarianism and Executive Compensation: A Relational Argument, by Pierre-Yves Néron Abstract: What, if anything, is wrong with high executive compensation?
A “Relational” Approach to Egalitarianism & Executive Compensation
A new paper by one of our favourite authors, in the latest issue of the Journal of Business Ethics. >>> Egalitarianism and Executive Compensation: A Relational Argument, by Pierre-Yves Néron Abstract: What, if anything, is wrong with high executive compensation?
HR Departments as Ethics Champions
What’s the role of HR departments in corporate ethics? The piece linked below suggests a dual role. First, HR is often the “home” for ethics policies (e.g., codes of ethics) and ethics training. Secondly, HR is the source of a
HR Departments as Ethics Champions
What’s the role of HR departments in corporate ethics? The piece linked below suggests a dual role. First, HR is often the “home” for ethics policies (e.g., codes of ethics) and ethics training. Secondly, HR is the source of a
Martin Shkreli, Stock Manipulation: Victimless Crimes (or Crimeless Victims?)
This looks more or less like a victimless crime. Turing Pharamaceuticals CEO Martin Shkreli is in the news again. This time, it’s because of his activity in the stock market. Basically, he bought up controlling shares in a dying drug
Martin Shkreli, Stock Manipulation: Victimless Crimes (or Crimeless Victims?)
This looks more or less like a victimless crime. Turing Pharamaceuticals CEO Martin Shkreli is in the news again. This time, it’s because of his activity in the stock market. Basically, he bought up controlling shares in a dying drug
Business Ethics Highlights 
Recent Comments